Fidelity Investments
LCTX icon

Fidelity Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Fidelity Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Sell
192,926
-382
-0.2% -$528 ﹤0.01% 3562
2026
Q1 		$305K Buy
193,308
+1,348
+0.7% +$2.27K ﹤0.01% 3314
2025
Q4 		$321K Sell
191,960
-2,068
-1% -$3.58K ﹤0.01% 3243
2025
Q3 		$328K Sell
194,028
-862
-0.4% -$1.02K ﹤0.01% 3191
2025
Q2 		$177K Sell
194,890
-9,216
-5% -$5.47K ﹤0.01% 3356
2025
Q1 		$92.2K Buy
204,106
+3,201
+2% +$1.88K ﹤0.01% 3589
2024
Q4 		$101K Buy
200,905
+194,495
+3,034% +$143K ﹤0.01% 3544
2024
Q3 		$5.8K Buy
6,410
+4,537
+242% +$4.21K ﹤0.01% 4590
2024
Q2 		$1.87K Sell
1,873
-228
-11% -$252 ﹤0.01% 4734
2024
Q1 		$3.11K Buy
2,101
+751
+56% +$851 ﹤0.01% 4615
2023
Q4 		$1.47K Sell
1,350
-94
-7% -$103 ﹤0.01% 4703
2023
Q3 		$1.7K Sell
1,444
-649
-31% -$883 ﹤0.01% 4576
2023
Q2 		$2.95K Buy
2,093
+1,249
+148% +$1.73K ﹤0.01% 4503
2023
Q1 		$1.27K Buy
844
+62
+8% +$87 ﹤0.01% 4709
2022
Q4 		$915 Sell
782
-236
-23% -$297 ﹤0.01% 4669
2022
Q3 		$1K Sell
1,018
-4,408
-81% -$6.47K ﹤0.01% 4697
2022
Q2 		$9K Buy
5,426
+3,744
+223% +$4.94K ﹤0.01% 4143
2022
Q1 		$2K Buy
1,682
+1,680
+84,000% +$2.61K ﹤0.01% 4676
2021
Q4 		$0 Hold
2
– – ﹤0.01% 4694
2021
Q3 		$0 Sell
2
-3
-60% -$8 ﹤0.01% 4732
2021
Q2 		$0 Buy
+5
New +$13 ﹤0.01% 4604
2020
Q1 		– Sell
-500
Closed – – 4001
2019
Q4 		$0 Buy
+500
New +$417 ﹤0.01% 4067
2019
Q3 		– Sell
-493
Closed -$1K – 4044
2019
Q2 		$1K Buy
493
+473
+2,365% +$545 ﹤0.01% 3614
2019
Q1 		$0 Buy
+20
New +$25 ﹤0.01% 3949
2014
Q1 		– Sell
-759,946
Closed -$2.21M – 2688
2013
Q4 		$2.21M Sell
759,946
-1,038,480
-58% -$3.14M ﹤0.01% 2333
2013
Q3 		$5.52M Sell
1,798,426
-82,270
-4% -$260K ﹤0.01% 2131
2013
Q2 		$6.01M Buy
+1,880,696
New +$6.02M ﹤0.01% 2086

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's LCTX Position: Q2 2026 in Review

Fidelity Investments reduced its Lineage Cell Therapeutics (LCTX) stake by 0.2% in Q2 2026, selling an estimated $528 and leaving 192,926 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #3562.

Fidelity Investments first reported a position in LCTX in Q2 2013 and has held it in 27 quarters since. The position peaked at $6.01M in Q2 2013. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Fidelity Investments held 192,926 shares of Lineage Cell Therapeutics worth $253K as of Q2 2026.
  • Fidelity Investments sold 382 Lineage Cell Therapeutics shares in Q2 2026, an estimated $528.
  • Lineage Cell Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3562 holding.
  • Fidelity Investments first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 27 quarters since.
  • Fidelity Investments's Lineage Cell Therapeutics position peaked at $6.01M in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.